An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Public ClinicalTrials.gov record NCT05217628. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II/III, Multicentre, 8-week run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, With a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 mg Basimglurant in Patients With Pain Associated With Trigeminal Neuralgia With Suboptimal Response to Their Current Anti-pain Therapy.
Study identification
- NCT ID
- NCT05217628
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Noema Pharma AG
- Industry
- Enrollment
- 166 participants
Conditions and interventions
Conditions
Interventions
- Basimglurant Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2022
- Primary completion
- Feb 1, 2027
- Completion
- Apr 23, 2027
- Last update posted
- Jan 22, 2026
2022 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaizen Brain Center (Site #: 1001) | La Jolla | California | 92037 | — |
| L & A Morales Healthcare INC (Site#: 1011) | Miami | Florida | 33142-3911 | — |
| University of South Florida (Site #: 1002) | Tampa | Florida | 33612 | — |
| Vista Clinical Research,LLC (Site#: 1010) | Newnan | Georgia | 30265 | — |
| Beth Israel Deaconess Medical Center (Site #: 1004) | Boston | Massachusetts | 02215 | — |
| Altea Research - Nevada - ClinEdge - PPDS (Site #1006) | Las Vegas | Nevada | 89102-1972 | — |
| Columbia University - Irving Medical Center (Site #: 1008) | New York | New York | 10032 | — |
| University of Cincinnati (Site #: 1007) | Cincinnati | Ohio | 45219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05217628, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05217628 live on ClinicalTrials.gov.